Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anteris Technologies Global Corp.AVR · Entity 5089 | Director | June 07, 2026 | June 10, 2026 |
| LEMAITRE VASCULAR INCLMAT · Entity 1927 | Director · President and Director | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anteris Technologies Global Corp.
Report date June 07, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,580 |
Reported balance
After 2026-06-07 transaction · row 1
1 source rowRow 1 · 2026-06-07 · Exercise / conversion · Acquired 17,580 · Balance 17,580 F1: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,162 |
Reported balance
After 2026-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-07 · Exercise / conversion · Disposed 17,580 · Balance 35,162 F1: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis. F2: On December 3, 2025, the reporting person was granted 52,742 RSUs that generally vest in approximately equal installments on June 7, 2026, June 7, 2027 and June 7, 2028, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") converts into a share of common stock on a one-for-one basis.
F2: On December 3, 2025, the reporting person was granted 52,742 RSUs that generally vest in approximately equal installments on June 7, 2026, June 7, 2027 and June 7, 2028, subject to the Reporting Person's continued service through each vesting date.
LEMAITRE VASCULAR INC
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 25.4682 |
Reported balance
After 2026-09-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-03 · Grant · Acquired 2.1262 · Balance 25.4682 F1: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 24.7852 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Grant · Acquired 2.1262 · Balance 24.7852 F2: These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 30.34 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Grant · Acquired 3.6322 · Balance 30.34 F3: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 32.3815 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Grant · Acquired 4.3524 · Balance 32.3815 F4: These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 17.5403 |
Reported balance
After 2026-09-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-03 · Grant · Acquired 3.1566 · Balance 17.5403 F5: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 18.6239 |
Reported balance
After 2026-09-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-03 · Grant · Acquired 3.5757 · Balance 18.6239 F6: These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 1.9861 |
Reported balance
After 2026-09-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-03 · Grant · Acquired 0.3056 · Balance 1.9861 F7: These dividend equivalent rights accrued on a restricted stock unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 2.0893 |
Reported balance
After 2026-09-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-03 · Grant · Acquired 0.3453 · Balance 2.0893 F8: These dividend equivalent rights accrued on a performance share unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
| Dividend Equivalent RightsSEC Table II · derivative / convertible security | Direct | 13.6627 |
Reported balance
After 2026-09-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-03 · Grant · Acquired 5.2874 · Balance 13.6627 F9: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F2: These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F3: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F4: These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F5: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F6: These dividend equivalent rights accrued on a performance share unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F7: These dividend equivalent rights accrued on a restricted stock unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F8: These dividend equivalent rights accrued on a performance share unit award granted on 2/18/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F9: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2016 Filed Oct 17, 2016 20:30 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-16-146050 · doc4.xml · derivative · entry 4 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2017-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 13, 2016 Filed Oct 17, 2016 20:30 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,552 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001209191-16-146050 · doc4.xml · derivative · entry 3 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,552 shares Expires 2016-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 13, 2016 Filed Oct 17, 2016 20:30 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | Exercise / conversionCommon Stock | 1,500 | $4.70 | $7,050.00 |
DisclosureSEC source: 0001209191-16-146050 · doc4.xml · nonDerivative · entry 2 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. Read SEC document |
| October 13, 2016 Filed Oct 17, 2016 20:30 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | Exercise / conversionCommon Stock | 1,552 | $4.41 | $6,844.32 |
DisclosureSEC source: 0001209191-16-146050 · doc4.xml · nonDerivative · entry 1 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 20:14 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 6,452 | $21.05 | $135,829.44 |
DisclosureSEC source: 0001209191-16-142152 · doc4.xml · nonDerivative · entry 1 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,793 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $21.00 to $21.09. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 20:46 UTC Amendment | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 3,548 | $21.02 | $74,591.38 |
DisclosureSEC source: 0001209191-16-141805 · doc4a.xml · nonDerivative · entry 2 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,245 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $21.00 to $21.14. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 20:30 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 3,548 | $21.02 | $74,591.38 |
DisclosureSEC source: 0001209191-16-141791 · doc4.xml · nonDerivative · entry 2 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,245 F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $21.00 to $21.14. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:46 UTC Amendment | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 30,000 | $20.33 | $609,999.00 |
DisclosureSEC source: 0001209191-16-141805 · doc4a.xml · nonDerivative · entry 1 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,793 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $20.18 to $20.55. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:30 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 30,000 | $20.33 | $609,999.00 |
DisclosureSEC source: 0001209191-16-141791 · doc4.xml · nonDerivative · entry 1 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,793 F1 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $20.18 to $20.55. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| September 07, 2016 Filed Sep 8, 2016 21:49 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 10,000 | $20.77 | $207,678.00 |
DisclosureSEC source: 0001209191-16-140613 · doc4.xml · nonDerivative · entry 2 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,793 F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $20.60 to $20.91. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 21:49 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 9 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-140613 · doc4.xml · derivative · entry 3 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9 Underlying: Common Stock · 9 shares Expires not disclosed F3 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 7/25/2016 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F3 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 7/25/2016 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F3 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 7/25/2016 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 21:49 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 10,000 | $19.36 | $193,624.00 |
DisclosureSEC source: 0001209191-16-140613 · doc4.xml · nonDerivative · entry 1 Roberts David B · CIK 0001365731 · Director · President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,793 F1 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $19.02 to $19.80. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.